Disease/Infection News

RSS

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

Researchers evaluated clinical accuracy and analytical detection capabilities of the two US Food and Drug Administration-approved rapid antigen tests across SARS-CoV-2 variants.

25 Mar 2022

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Researchers used a CNN regression model to investigate the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex.

25 Mar 2022

Understanding a New Mutation in Pediatric AML

News-Medical speaks to Dr. Jeffery Klco about acute myeloid leukemia (AML) and his recent research that is helping us to understand a new mutation in pediatric AML.

25 Mar 2022

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection incites adaptive cellular immune responses. In many SARS-CoV-2 studies, peripheral blood is analyzed to study the immune responses. Now, a new study under consideration at the Nature Portfolio Journal analyzes the peripheral blood, tonsils, and adenoids of children to understand local and systemic immune responses to SARS-CoV-2.

25 Mar 2022

Study shows third dose of Pfizer-BioNTech vaccine against COVID-19 is both safe and effective

A research paper published in the New England Journal of Medicine has demonstrated how a third dose of Pfizer-BioNTech (BNT162b2) vaccine administered in a median period of 10.8 months after the second one bestowed 95.3% efficacy against coronavirus disease 2019 (COVID-19), in comparison with two doses of the same vaccine during a median follow-up of 2.5 months.

24 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Extensive immediate actions needed for global control of tuberculosis

Announcing a new article publication for Zoonoses journal. In this article the authors discuss how extensive immediate actions worldwide are required to progress toward a tuberculosis-free world.

24 Mar 2022

IgG Fc glycosylation: A marker for severe COVID-19

Researchers suggest that low anti-spike IgG1 glycosylation, sialyation, and high bisection are markers of severe COVID-19.

24 Mar 2022

The intercontinental spread of high-pathogenic avian influenza A (H5N1) virus

Researchers aim to better understand the landscape movement of the avian influenza virus.

24 Mar 2022

Brain fog in post-COVID Canadians

A new study confirms that a history of COVID-19 is a risk factor for cognitive dysfunction in the young and middle-aged.

24 Mar 2022

Breast milk components show potent in vitro SARS-CoV-2 inhibition

Human breastmilk contains substances that can inhibit infection by SARS-CoV-2 and its variants, as well as prevent its replication.

24 Mar 2022

Shorter course of antibiotics associated with fewer antibiotic resistance genes

Antibiotic resistance is a growing problem worldwide that threatens the efficacy of available treatments and can lead to extended hospital stays and increased mortality.

24 Mar 2022

Tuberculosis perturbs epigenetic processes to promote premature cellular aging

Tuberculosis (TB) is a potentially serious infectious disease caused by a type of bacterium called Mycobacterium tuberculosis.

24 Mar 2022

INRS professor developing a glycoconjugate vaccine for melioidosis

The threat from Melioidosis is real. The bacterium that causes this infectious multisymptom illness is resistant to antibiotics, making diagnosis and treatment more complex and resulting in a mortality rate of up to 50%.

24 Mar 2022

Aspirin use associated with lower rates of death in hospitalized COVID-19 patients

Researchers at the George Washington University published findings from the world's largest cohort study showing that hospitalized patients with moderate COVID-19 who were given aspirin early on in their treatment had a lower risk of dying compared to patients who were not given aspirin.

24 Mar 2022

Disease/Infection News

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Understanding a New Mutation in Pediatric AML

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

Study shows third dose of Pfizer-BioNTech vaccine against COVID-19 is both safe and effective

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

Extensive immediate actions needed for global control of tuberculosis

IgG Fc glycosylation: A marker for severe COVID-19

The intercontinental spread of high-pathogenic avian influenza A (H5N1) virus

Brain fog in post-COVID Canadians

Breast milk components show potent in vitro SARS-CoV-2 inhibition

Shorter course of antibiotics associated with fewer antibiotic resistance genes

Tuberculosis perturbs epigenetic processes to promote premature cellular aging

INRS professor developing a glycoconjugate vaccine for melioidosis

Aspirin use associated with lower rates of death in hospitalized COVID-19 patients

U of A researcher receives $436,642 from NIH to study effects of SARS-COV-2 on the aortic valve

Short duration treatment effective in combating most childhood TB cases, study says

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News